Company: PTPI
Filing Date: 2025-02-19
Form Type: 424B4
Source: 0001410578-25-000164
Chunk: 236

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-02-19
Form: 424B4
Chunk 236
---
737 |
| Total segment assets   | ​ | $            | 27,891,180 | ​ | $               | 5,904,615 | ​ | $            | 33,795,795 |

The Company’s assets by reportable segment and reconciliation of segment assets to consolidated assets as of December 31, 2022, are summarized as follows:

| ​                      
 ​                      
 ​                      | ​ 
 ​ | ​            
 Prescription 
 Medications  |          ​ | ​ 
 ​ | ​               
 ​               
 Medical Devices |         ​ 
         ​ | ​ 
 ​ | ​            
 ​            
 Consolidated |          ​ 
          ​ |
|:-----------------------|:--|:-------------|-----------:|:--|:----------------|----------:|:--|:-------------|-----------:|
| Intangible assets, net | ​ | $            |  7,178,704 | ​ | $               | 5,065,780 | ​ | $            | 12,244,484 |
| Total segment assets   | ​ | $            | 25,831,048 | ​ | $               | 6,590,166 | ​ | $            | 32,421,214 |

19) Private Placement On July 13, 2023, we entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain accredited investors (the “Investors”), pursuant to which we agreed to sell in a private placement to the Investors (i) an aggregate of 15,000 shares of our newly-designated Series A Convertible Preferred Stock, with a par value of $0.0001 per share and a stated value of $1,000 per share (the “Series A Preferred Stock”), initially convertible into up to 6,666,668 shares of our common stock, par value $0.0001 per share (the “Common Stock”) at an initial conversion price of $2.25 per share (the “Series A Preferred Shares”), and (ii) warrants to acquire up to an aggregate of 6,666,668 shares of Common Stock (the “Warrants”) at an initial exercise price of $2.25 per share (collectively, the “Private Placement”). Pursuant to the terms of the Certificate of Designations of Series A Convertible Preferred Stock (the “Certificate of Designations”) and the Warrants, each of the Conversion Price (as defined below) and the exercise price and the number of shares underlying the Warrants is subject to